RSS

Gram-negative multidrug-resistant pathogens

The AMR Centre (AMRC) and EligoChem have entered into an agreement for the co-development of antimicrobial peptides to treat drug-resistant Gram-negative bacteria, such as E. coli. more

News

A specialist in therapeutic approaches to treat resistant bacterial infections, Mutabilis has been selected to join the European consortium ENABLE — aimed at developing antibiotics to tackle infections caused by multi-resistant gram-negative bacteria more

News

Biopharmaceutical company, Antabio, has completed a €7.3 million series A financing round for the development of novel therapies to treat drug-resistant gram-negative infections. more

News

Cheshire-based R&D facility for new antibiotics and diagnostics, the AMR Centre, has signed a deal with US biotech company, Microbiotix, for the co-development of a bacterial virulence drug candidate. more

News

Polyphor has been awarded with its first milestone payment from the Wellcome Trust ahead of schedule for the development of novel antibiotics against Gram-negative multidrug-resistant pathogens. more

News